Please login to the form below
hepatitis C
This page shows the latest hepatitis C news and features for those working in and with pharma, biotech and healthcare.
Gilead’s Q1 revenues lifted by COVID-19 med Veklury as HIV drugs take a hit
Sales of Gilead's hepatitis C virus (HCV) products and hepatitis delta virus (HDV) products increased by 18% to $220m, with a significant increase in sales of chronic hepatitis B virus
Latest news
-
Pfizer CEO says oral COVID-19 pill could be ready by the end of the year
Previously, protease inhibitors have been shown to be effective for the treatment of other viral pathogens, including HIV and hepatitis C virus when used alone or in combination with other antivirals.
-
FDA removes clinical hold on uniQure’s haemophilia gene therapy
This included a 25-year history of hepatitis C (HCV) as well as a history of hepatitis B (HBV).
-
Pfizer launches early study of COVID-19 antiviral therapeutic
Previously, protease inhibitors have been effective for the treatment of other viral pathogens, including HIV and hepatitis C virus, when administered alone and in combination with additional antivirals.
-
Gilead’s COVID-19 drug Veklury brought in almost $2bn in Q4
2020. Its hepatitis C virus (HCV) business also took a major hit, slipping by 33% to $423m in the fourth quarter and 30% to $2.1bn for the full year compared
-
Merck’s appeal to restore hepatitis C patent verdict against Gilead fails
Merck &Co’s appeal to restore a verdict against Gilead for infringing on a patent relating to a hepatitis C virus (HCV) treatment has been rejected by the US Supreme Court. ... Idenix discovered that a single type of modified ribonucleoside inhibits
More from news
Approximately 99 fully matching, plus 269 partially matching documents found.
Latest Intelligence
-
As the opioid crisis grabs the headlines, the search for safe treatments continues
The figure I use is 70-60-50. It reduces the mortality risk by 70%, lowers the risk of hepatitis C infection by 60% and has a 50% lower risk of
-
The Golden Goose
When the NHS finally did approve the life-saving hepatitis C treatments, it rationed access to only the sickest patients.
-
25 Women Leaders in UK Healthcare (part 2)
It has brought to market not one but two groundbreaking drugs in hepatitis C, Harvoni, and in diffuse large B cell lymphoma, Yescarta, one of the first CAR-T therapies to ... After all this time, Hilary said she has to remind her team how remarkable the
-
Bluebird: on a mission to ‘recode’ the DNA of healthcare
The huge global success of Netflix has also made it a reference point, with health payers in the US and Australia recently signing ‘subscription’ arrangements to finance expanded spending on hepatitis
-
Vertex: a vision of treating all CF patients worldwide draws closer
a decade of trial and error, the company had a huge breakthrough drug on its hands: hepatitis C treatment Incivek.
More from intelligence
Approximately 2 fully matching, plus 38 partially matching documents found.
Latest appointments
-
Red Door Unlimited appoints new digital strategy head
Prior to joining the agency, Morgan worked on accounts in patient advocacy for cancer immunotherapy, hepatitis C treatments and migraines for Firstlight PR and Hill and Knowlton Strategies.
-
Packer Forbes appoints Jade McCudden
McCudden has worked across a number of disease areas including hepatitis C, anticoagulation, Alzheimer's disease, women's health, melanoma and nicotine replacement therapy.
-
Clark Health Communications make three team additions
range of therapy areas including hepatitis C, rare disease and gynaecology.
-
Cidara Therapeutics makes senior appointments
He joins from BMS, where he served as VP of the US viral hepatitis franchise, which is responsible for leading the US launch platform in hepatitis C and running the hepatitis
-
Medivir names new CEO
His other roles include CEO of Pfizer's business in Sweden. Commenting on his new position, he highlighted Medivir's work with Johnson &Johnson to develop the hepatitis C treatment Olysio
More from appointments
Approximately 0 fully matching, plus 8 partially matching documents found.
Latest from PMHub
-
Hepatitis (C)an’t wait: taking a de-centralized approach to cure the epidemic
Despite huge advances in the field, the burden of hepatitis C remains a significant public health problem. ... The World Health Organization (WHO) estimates that 71 million people globally have chronic hepatitis C.
-
Precision medicine with precision management and precision pricing; ensuring affordability in the cell and gene therapy era
Insurance carve outs, reinsurance and specific contractual arrangements. The “Netflix” example of the Louisiana state approach to hepatitis C elimination which is based on unlimited access for a pre-specified budget
-
emotive adds to medical team with new Scientific Lead and Associate Medical Writer
in rare diseases such as Gaucher disease and Cushing’s disease and in hepatitis C.
-
Improving Outcomes in the Treatment of Opioid Dependence Highlights Report
For the third year in a row, the IOTOD conference dedicated an entire session to hepatitis C virus (HCV).
-
TVF Communications shortlisted for the second year in a row for Writing Excellence award at Communique 2017
We created an eLearning Programme that was initiated to educate internal AbbVie stakeholders on hepatitis C virus (HCV).
More from PMHub
Approximately 3 fully matching, plus 12 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Vice President, Medical Communications, UK, six figure package
-
Six figure salary
- Senior Analyst, Market Access, UK, Home based
-
Highly competitive salary
- Scientific Strategy Lead, Medical Communications, UK
-
Highly competitive salary
- Medical Writer, MRNA/ Covid 19, Medical Communications, UK
-
Highly competitive salary
- MSD and AstraZeneca announce phase 3 results for prostate cancer therapy
- Biogen and Happify Health team up to create digital platform for MS patients
- Novartis publishes final positive phase 3 results of Zolgensma in Nature Medicine
- Myovant Sciences and Pfizer publish phase 3 results for endometriosis therapy
- Bristol Myers Squibb announces positive trial results for treatment of MS
- FDA grants Pfizer/BioNTech’s COVID-19 vaccine emergency use authorisation for infants
- Virtual MSL/Sales training programs and events
- 6 trends shaping the future of personalized medicine
- Omnichannel strategies to revolutionize the healthcare professional experience
- The digital-first launch: the key to connected stakeholder experiences?
- Pfizer and BioNTech share positive results for Omicron-adapted COVID-19 vaccine
- Bristol Myers Squibb announces positive trial results for treatment of MS
- MSD and AstraZeneca announce phase 3 results for prostate cancer therapy
- Roche shares new positive Ocrevus data for MS patients
- College of Medicine launches Beyond Pills campaign to tackle overprescribing in UK health system
- Annovis Bio’s lead therapeutic shows ‘significant improvements’ in Alzheimer’s, Parkinson’s
- Phase 3 trial initiated to evaluate AZ's Saphnelo in lupus nephritis
- New virtual health and care report from WHO and Novartis calls for ‘critical action’
PMHub
IGNIFI
We’re IGNIFI. An independent creative agency, we help spark and sustain successful brands for some of the biggest names in...
Latest intelligence
- Virtual MSL/Sales training programs and events
- Top 10 ways to leverage the Impetus InSite Platform® for internal MSL/Sales training programs and events...
- 6 trends shaping the future of personalized medicine
- Senior Consultant Leah Carlisle explores the key trends discussed at the 16th annual Personalized Medicine Conference, providing expert analysis and key recommendations for biopharmaceutical innovators....
- Omnichannel strategies to revolutionize the healthcare professional experience
- Fishawack Health’s omnichannel experts unite to reveal how medical and commercial teams can build more meaningful experiences for healthcare professionals. They discuss the opportunities of omnichannel and explore how the...
